Skip to Content

Exelixis Inc EXEL Stock Quote

| Rating as of

NASDAQ:EXEL

Morningstar‘s Stock Analysis EXEL

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Exelixis Posts Q3 Results in Line With Expectations; Maintaining $18.90 FVE, Shares Fairly Valued

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Exelixis reported third-quarter results in line with our expectations, highlighted by revenue of nearly $412 million, representing a 25% increase from the prior-year period thanks to strong performance of its cabozantinib franchise. Exelixis is tracking our expectations, and we maintain our fair value estimate of $18.90 per share, no-moat rating, and stable moat trend. We view shares as fairly valued, currently trading in 3-star territory.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics EXEL

Company Profile EXEL

Business Description

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Contact
1851 Harbor Bay Parkway
Alameda, CA, 94502
T +1 650 837-7000
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 954

Related News EXEL